Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 32% ± 16% | |
peripheral blood | 14 studies | 25% ± 7% | |
brain | 12 studies | 32% ± 19% | |
eye | 10 studies | 32% ± 16% | |
kidney | 9 studies | 34% ± 10% | |
intestine | 8 studies | 28% ± 11% | |
liver | 6 studies | 26% ± 16% | |
bone marrow | 5 studies | 19% ± 2% | |
heart | 5 studies | 27% ± 4% | |
lymph node | 5 studies | 27% ± 8% | |
uterus | 4 studies | 30% ± 14% | |
adrenal gland | 3 studies | 26% ± 1% | |
thymus | 3 studies | 50% ± 23% | |
breast | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 8818.72 | 358 / 359 | 100% | 68.81 | 286 / 286 |
intestine | 100% | 8204.13 | 964 / 966 | 100% | 79.47 | 526 / 527 |
kidney | 100% | 10976.06 | 89 / 89 | 100% | 94.47 | 897 / 901 |
bladder | 100% | 6071.76 | 21 / 21 | 99% | 89.19 | 501 / 504 |
esophagus | 99% | 7587.00 | 1434 / 1445 | 100% | 62.05 | 183 / 183 |
breast | 100% | 8328.34 | 457 / 459 | 100% | 94.78 | 1114 / 1118 |
adrenal gland | 100% | 12438.72 | 258 / 258 | 99% | 130.08 | 228 / 230 |
skin | 99% | 6335.73 | 1784 / 1809 | 100% | 135.88 | 472 / 472 |
brain | 98% | 17300.45 | 2587 / 2642 | 100% | 109.99 | 705 / 705 |
thymus | 98% | 4936.66 | 638 / 653 | 100% | 99.83 | 603 / 605 |
prostate | 97% | 4672.42 | 237 / 245 | 99% | 81.41 | 499 / 502 |
uterus | 96% | 4465.14 | 163 / 170 | 100% | 114.44 | 458 / 459 |
ovary | 96% | 3773.22 | 172 / 180 | 100% | 69.25 | 430 / 430 |
liver | 94% | 5530.15 | 212 / 226 | 100% | 96.39 | 404 / 406 |
lung | 86% | 3975.19 | 496 / 578 | 100% | 93.36 | 1155 / 1155 |
pancreas | 55% | 1727.48 | 180 / 328 | 100% | 66.57 | 178 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 152.49 | 29 / 29 |
tonsil | 0% | 0 | 0 / 0 | 100% | 111.15 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 32.80 | 1 / 1 |
muscle | 100% | 16692.35 | 800 / 803 | 0% | 0 | 0 / 0 |
adipose | 99% | 9386.13 | 1197 / 1204 | 0% | 0 | 0 / 0 |
spleen | 99% | 4583.66 | 238 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 96.86 | 79 / 80 |
blood vessel | 99% | 5731.84 | 1315 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 42053.30 | 836 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 32% | 3757.62 | 298 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006739 | Biological process | NADP metabolic process |
GO_0006108 | Biological process | malate metabolic process |
GO_0006734 | Biological process | NADH metabolic process |
GO_0006094 | Biological process | gluconeogenesis |
GO_0006099 | Biological process | tricarboxylic acid cycle |
GO_0006107 | Biological process | oxaloacetate metabolic process |
GO_0005813 | Cellular component | centrosome |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0004470 | Molecular function | malic enzyme activity |
GO_0030060 | Molecular function | L-malate dehydrogenase (NAD+) activity |
GO_0047860 | Molecular function | diiodophenylpyruvate reductase activity |
GO_0005515 | Molecular function | protein binding |
GO_0047995 | Molecular function | hydroxyphenylpyruvate reductase activity |
Gene name | MDH1 |
Protein name | Malate dehydrogenase 1 Malate dehydrogenase (EC 1.1.1.37) Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Aromatic alpha-keto acid reductase) (KAR) (EC 1.1.1.96) (Cytosolic malate dehydrogenase) Malate dehydrogenase, cytoplasmic (EC 1.1.1.96) (Aromatic alpha-keto acid reductase) (Cytosolic malate dehydrogenase) |
Synonyms | MDHA |
Description | FUNCTION: Catalyzes the reduction of aromatic alpha-keto acids in the presence of NADH . Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply for oxidative phosphorylation . Catalyzes the reduction of 2-oxoglutarate to 2-hydroxyglutarate, leading to elevated reactive oxygen species (ROS) . . |
Accessions | ENST00000421012.2 ENST00000544381.4 [P40925-1] A0A5K1VW95 ENST00000442225.5 C9JLV6 ENST00000409476.5 P40925 B9A041 B8ZZ51 ENST00000233114.13 [P40925-1] ENST00000409908.5 F8WFC2 ENST00000432309 ENST00000454035.5 ENST00000432309.6 [P40925-3] C9JF79 ENST00000436321.5 ENST00000539945.7 C9JRL4 C9IZI0 |